These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 26362823

  • 1. Protective effect of the multitarget compound DPH-4 on human SSAO/VAP-1-expressing hCMEC/D3 cells under oxygen-glucose deprivation conditions: an in vitro experimental model of cerebral ischaemia.
    Sun P, Esteban G, Inokuchi T, Marco-Contelles J, Weksler BB, Romero IA, Couraud PO, Unzeta M, Solé M.
    Br J Pharmacol; 2015 Nov; 172(22):5390-402. PubMed ID: 26362823
    [Abstract] [Full Text] [Related]

  • 2. Involvement of SSAO/VAP-1 in oxygen-glucose deprivation-mediated damage using the endothelial hSSAO/VAP-1-expressing cells as experimental model of cerebral ischemia.
    Sun P, Solé M, Unzeta M.
    Cerebrovasc Dis; 2014 Nov; 37(3):171-80. PubMed ID: 24503888
    [Abstract] [Full Text] [Related]

  • 3. Blood-brain barrier dysfunction underlying Alzheimer's disease is induced by an SSAO/VAP-1-dependent cerebrovascular activation with enhanced Aβ deposition.
    Solé M, Esteban-Lopez M, Taltavull B, Fábregas C, Fadó R, Casals N, Rodríguez-Álvarez J, Miñano-Molina AJ, Unzeta M.
    Biochim Biophys Acta Mol Basis Dis; 2019 Sep 01; 1865(9):2189-2202. PubMed ID: 31047972
    [Abstract] [Full Text] [Related]

  • 4. SSAO/VAP-1 in Cerebrovascular Disorders: A Potential Therapeutic Target for Stroke and Alzheimer's Disease.
    Unzeta M, Hernàndez-Guillamon M, Sun P, Solé M.
    Int J Mol Sci; 2021 Mar 25; 22(7):. PubMed ID: 33805974
    [Abstract] [Full Text] [Related]

  • 5. Vascular cell lines expressing SSAO/VAP-1: a new experimental tool to study its involvement in vascular diseases.
    Solé M, Unzeta M.
    Biol Cell; 2011 Nov 25; 103(11):543-57. PubMed ID: 21819380
    [Abstract] [Full Text] [Related]

  • 6. Cross-talk between Aβ and endothelial SSAO/VAP-1 accelerates vascular damage and Aβ aggregation related to CAA-AD.
    Solé M, Miñano-Molina AJ, Unzeta M.
    Neurobiol Aging; 2015 Feb 25; 36(2):762-75. PubMed ID: 25457560
    [Abstract] [Full Text] [Related]

  • 7. Simvastatin blocks soluble SSAO/VAP-1 release in experimental models of cerebral ischemia: Possible benefits for stroke-induced inflammation control.
    Sun P, Hernandez-Guillamón M, Campos-Martorell M, Simats A, Montaner J, Unzeta M, Solé M.
    Biochim Biophys Acta Mol Basis Dis; 2018 Feb 25; 1864(2):542-553. PubMed ID: 29175057
    [Abstract] [Full Text] [Related]

  • 8. Soluble Vascular Adhesion Protein-1 Mediates Spermine Oxidation as Semicarbazide-Sensitive Amine Oxidase: Possible Role in Proliferative Diabetic Retinopathy.
    Murata M, Noda K, Kawasaki A, Yoshida S, Dong Y, Saito M, Dong Z, Ando R, Mori S, Saito W, Kanda A, Ishida S.
    Curr Eye Res; 2017 Dec 25; 42(12):1674-1683. PubMed ID: 28937866
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Semicarbazide sensitive amine oxidase overexpression has dual consequences: insulin mimicry and diabetes-like complications.
    Stolen CM, Madanat R, Marti L, Kari S, Yegutkin GG, Sariola H, Zorzano A, Jalkanen S.
    FASEB J; 2004 Apr 25; 18(6):702-4. PubMed ID: 14977883
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. VAP-1/SSAO plasma activity and brain expression in human hemorrhagic stroke.
    Hernandez-Guillamon M, Solé M, Delgado P, García-Bonilla L, Giralt D, Boada C, Penalba A, García S, Flores A, Ribó M, Alvarez-Sabin J, Ortega-Aznar A, Unzeta M, Montaner J.
    Cerebrovasc Dis; 2012 Apr 25; 33(1):55-63. PubMed ID: 22133888
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of semicarbazide-sensitive amine oxidase reduces atherosclerosis in apolipoprotein E-deficient mice.
    Wang SH, Yu TY, Tsai FC, Weston CJ, Lin MS, Hung CS, Kao HL, Li YI, Solé M, Unzeta M, Chen YL, Chuang LM, Li HY.
    Transl Res; 2018 Jul 25; 197():12-31. PubMed ID: 29653075
    [Abstract] [Full Text] [Related]

  • 16. Plasma VAP-1/SSAO activity predicts intracranial hemorrhages and adverse neurological outcome after tissue plasminogen activator treatment in stroke.
    Hernandez-Guillamon M, Garcia-Bonilla L, Solé M, Sosti V, Parés M, Campos M, Ortega-Aznar A, Domínguez C, Rubiera M, Ribó M, Quintana M, Molina CA, Alvarez-Sabín J, Rosell A, Unzeta M, Montaner J.
    Stroke; 2010 Jul 25; 41(7):1528-35. PubMed ID: 20538694
    [Abstract] [Full Text] [Related]

  • 17. Adipocytes release a soluble form of VAP-1/SSAO by a metalloprotease-dependent process and in a regulated manner.
    Abella A, García-Vicente S, Viguerie N, Ros-Baró A, Camps M, Palacín M, Zorzano A, Marti L.
    Diabetologia; 2004 Mar 25; 47(3):429-438. PubMed ID: 14968297
    [Abstract] [Full Text] [Related]

  • 18. New efficient substrates for semicarbazide-sensitive amine oxidase/VAP-1 enzyme: analysis by SARs and computational docking.
    Yraola F, García-Vicente S, Fernandez-Recio J, Albericio F, Zorzano A, Marti L, Royo M.
    J Med Chem; 2006 Oct 19; 49(21):6197-208. PubMed ID: 17034126
    [Abstract] [Full Text] [Related]

  • 19. The contribution of cerebral vascular semicarbazide-sensitive amine oxidase to cerebral amyloid angiopathy in Alzheimer's disease.
    Jiang ZJ, Richardson JS, Yu PH.
    Neuropathol Appl Neurobiol; 2008 Apr 19; 34(2):194-204. PubMed ID: 17971074
    [Abstract] [Full Text] [Related]

  • 20. The release of soluble VAP-1/SSAO by 3T3-L1 adipocytes is stimulated by isoproterenol and low concentrations of TNFalpha.
    García-Vicente S, Abella A, Viguerie N, Ros-Baró A, Camps M, Testar X, Palacín M, Zorzano A, Marti L.
    J Physiol Biochem; 2005 Jun 19; 61(2):395-401. PubMed ID: 16180338
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.